4 news items
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
MBRX
7 May 24
therapy, regardless of whether the subject was deemed "fit" or "unfit" for intensive chemotherapy). Moleculin continues to recruit
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
MBRX
18 Apr 24
toxicity profile than traditional intensive therapy
Moleculin Biotech Provided A Preliminary Update On Recent Clinical Activity And Expected Near Term Milestones For Its Lead Program MB-106 For The Treatment Of Acute Myeloid Leukemia
MBRX
25 Mar 24
traditional intensive therapy
Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
MBRX
25 Mar 24
(in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than traditional intensive therapy
- Prev
- 1
- Next